Strategies to attenuate pathological remodeling in heart failure

Current Opinion in Cardiology

Volumn 24, Issue 3, 2009, Pages 223-229

  Eapen, Zubin ^a   Rogers, Joseph G ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Cardiac resynchronization therapy; Cardiac support device; Heart failure; Ventricular remodeling

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; SPIRONOLACTONE; VALSARTAN;

CARDIAC RESYNCHRONIZATION THERAPY; DEVICE; DRUG MECHANISM; FUNCTIONAL STATUS; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; MITRAL ANNULOPLASTY; MITRAL VALVE REGURGITATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HEART PACING;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC PACING, ARTIFICIAL; HEART FAILURE; HUMANS; MITRAL VALVE INSUFFICIENCY; MYOCARDIAL REVASCULARIZATION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 67651015857     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32832a11ff     Document Type: Review

References (55)

1. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57:84-95. (Pubitemid 15238844)
2. Sadoshima K, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin-II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75:977-984. (Pubitemid 24014554)
3. McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986; 74:693-702. (Pubitemid 16007186)
4. Katada J, Meguro T, Saito H, et al. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 2005; 111:2157-2164. (Pubitemid 40632429)
5. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990; 82:1724-1729.
6. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310.
7. Greenberg B, Quinones MA, Koilpillai C, et al., for the SOLVD Investigators. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995; 91:2573-2581.
8. Metra M, Nodari S, Parrinello G, et al. Marked improvement in left ventricular ejection fraction during long term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003; 145:292-299. (Pubitemid 36207951)
9. Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Val-HeFT echocardiography data. J Am Coll Cardiol 2004; 43:2022-2027. (Pubitemid 38686796)
10. Cintron G, Johnson G, Francis G, et al. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87 (Suppl 6):VI17-VI23. (Pubitemid 23164218)
11. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35:569-582. (Pubitemid 30167013)
12. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985; 72:406-412. (Pubitemid 15019891)
13. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
14. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992; 86:431-438.
15. Konstam MA, Kronenberg MW, Rousseau MF, et al., for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor, enalapril, on the longterm progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993; 88:2277-2283.
16. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.
17. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342:821-828.
18. Maggioni AP, Anand IS, Gottieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40:1414-1421.
19. Granger CB, McMurray JJV, Yusuf Y, et al. Effects of candesartan in patients with chronic heart failure and left ventricular systolic dysfunction intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772-776.
20. Sharpe N. Pharmacologic effects on cardiac remodeling. Curr Heart Fail Rep 2004; 1:9-13.
21. Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN). Cardiovasc Drugs Ther 2004; 18:57-66.
22. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357:1385-1390. (Pubitemid 32455364)
23. Doughty RN, Whalley GA, Walsh H, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN ECHO study. Circulation 2004; 109:201-206. (Pubitemid 38114140)
24. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease: Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29:1060-1066.
25. Lowes BD, Gill EA, Abraham WT, et al. The effect of carvedilol on the left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999; 83:1201-1205.
26. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
27. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial In Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283:1295-1302. (Pubitemid 30129796)
28. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321. (Pubitemid 36384098)
29. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
30. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26:809-820. (Pubitemid 24223231)
31. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990; 81:1161-1172. (Pubitemid 20119612)
32. Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27:1281-1292.
33. Pirolo JS, Hutchins GM, Moore GW. Infarct expansion: pathologic analysis of 204 patients with a single myocardial infarct. J Am Coll Cardiol 1986; 7:349-354. (Pubitemid 16164420)
34. Marino P, Zanolla L, Zardini P (GISSI). Effect of streptokinase on left ventricular modeling and function after myocardial infarction: the GISSI trial. J Am Coll Cardiol 1989; 14:1149-1158.
35. Touchstone DA, Beller GA, Nygaard TW, et al. Effects of successful intravenous reperfusion therapy on regional myocardial function and geometry in humans: a topographic assessment using two-dimensional echocardiography. J Am Coll Cardiol 1989; 13:1506-1513.
36. White HD, Cross DB, Elliott JM, et al. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994; 89:61-67. (Pubitemid 24026472)
37. Cabell CH, Trichon BH, Velazquez EJ, et al. Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) Echocardiographic study. Am Heart J 2004; 147:151-157.
38. Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol 2003; 91:538-543. (Pubitemid 36263251)
39. Acker MA, Bolling S, Shemin R, et al. Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. J Thorac Cardiovasc Surg 2006; 132:568-577. (Pubitemid 44278906)
40. Kass DA, Baughman KL, Pak PH, et al. Reverse remodeling from cardiomyoplasty in human heart failure. External constraint versus active assist. Circulation 1995; 91:2314-2318.
41. Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg 1998; 115:381-386.
42. Carraway EA, Rayburn BK. Device therapy for remodeling in congestive heart failure. Curr Heart Fail Rep 2007; 4:53-58. (Pubitemid 46663321)
43. Chaudhry PA, Mishima T, Sharov VG, et al. Passive epicardial containment prevents ventricular remodeling in heart failure. Ann Thorac Surg 2000; 70:1275-1280. (Pubitemid 30782161)
44. Shelton RJ, Velavan P, Nikitin NP, et al. Clinical trials update from the American Heart Association meeting: Acorn-CORCAP, Primary Care Trial of Chronic Disease Management, PEACE, CREATE, SHIELD, A-HeFT, GEMINI, Vitamin E Meta-analysis, ESCAPE, CARP, and SCD-HeFT Cost-effectiveness Study. Eur J Heart Fail 2005; 7:127-135. (Pubitemid 40092504)
45. Starling RC, Jessup M, Oh JK, et al. Sustained benefits of the CorCap cardiac support device on left ventricular remodeling: three year follow-up results from the Acorn clinical trial. Ann Thorac Surg 2007; 84:1236-1242. Three hundred patients with heart failure in the Acorn Randomized Trial were followed up with echocardiograms every 6 months. Patients treated with the CorCap CSD had significant reductions in LV volumes, which were maintained over 3 years of follow-up. The improvements in LV size and shape were observed when the CorCap was implanted concomitantly with mitral value surgery or by itself. (Pubitemid 47417856)
46. Klodell CT Jr, Aranda JM Jr, McGiffin DC, et al. Worldwide surgical experience with the Paracor HeartNet cardiac restraint device. J Thorac Cardiovasc Surg 2008; 135:188-195. Fifty-one patients with an ejection fraction of 35%or less, with a NYHA class II or III, and receiving optimal medical therapy for at least 3 months, underwent implantation of the HeartNet device. Six-month data demonstrated significant improvement in the 6-min walk test and Minnesota Living with Heart Failure Questionnaire and improvement in echocardiographic findings. The Paracor HeartNet device can be reliably implanted in patients with heart failure and marked reduction of LV function with a beneficial trend toward reverse remodeling.
47. http://clinicaltrials.gov/ct2/show/record/NCT00382863.
48. Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539-1549.
49. Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 2002; 105:438-445. (Pubitemid 34141699)
50. Rahmouni HW, Kirkpatrick JN, St John Sutton MG. Effects of cardiac resynchronization therapy on ventricular remodeling. Curr Heart Fail Rep 2008; 5:25-30.
51. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539-1549. (Pubitemid 40517094)
52. St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003; 107:1985-1990. (Pubitemid 36506071)
53. Sutton MG, Plappert T, Hilpisch KE, et al. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multi-center InSync Randomized Clinical Evaluation (MIRACLE). Circulation 2006; 113:266-272. (Pubitemid 43754384)
54. Yu CM, Bleeker GB, Fung JW, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 2005; 112:1580-1586. (Pubitemid 41324519)
55. Konstam MA, Udelson JE, Anand IS, Cohn JN. Ventricular remodeling in heart failure: a credible surrogate endpoint. J Cardiac Fail 2003; 9:350-353. (Pubitemid 37351801)